Skip to main content
SpringerLink
Log in

Clinical Pharmacokinetics of Sparfloxacin

  • Review Article
  • Drug Disposition
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

Summary

Sparfloxacin is a recently developed fluoroquinolone. The drug has shown potent antimicrobial activity against a wide range of Gram-positive and Gram-negative bacteria, glucose nonfermenters, anaerobes, Legionella spp., Mycoplasma spp., Chlamydia spp. and Mycobacterium spp. Methicillin-resistant Staphylococcus aureus is also susceptible to sparfloxacin.

Plasma sparfloxacin concentrations reach a peak (Cmax) of approximately 0.7 mg/L at 3 to 5 hours after a 200mg oral dose. This is followed by a monophasic slow decrease, with an elimination half-life (t½) of 15 to 20 hours. The Cmax and area under the plasma concentration-time curve show dose-related increases. Food intake does not affect the absorption and pharmacokinetics of sparfloxacin.

Sparfloxacin binds weakly to plasma protein (37%), and exhibits excellent tissue distribution and effective penetration into extracellular fluids. Concentrations of the drug in most tissues are similar to, or higher than, concomitant plasma concentrations. Sparfloxacin distributes slightly into cerebrospinal fluid. The drug is metabolised to a glucuronide. The urinary excretion of the unchanged drug accounts for 10 to 14% of the given dose. The ratio of Cmax values after multiple and single oral doses is 1.3 to 1.4, but other pharmacokinetic parameters of sparfloxacin are not influenced by multiple doses.

Even in patients with severe renal failure, no significant prolongation of the half-life is observed after oral administration. Sparfloxacin appears unlikely to affect the pharmacokinetics of theophylline. Antacids containing aluminium hydroxide reduce the oral bioavailability of sparfloxacin by 25 to 35%. Probenecid does not affect sparfloxacin pharmacokinetics. The pharmacokinetic properties of sparfloxacin allow once-daily administration in the treatment of various infections.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Akiyama H, Torigoe R, Yamada T, Abe Y, Kanamoto A, et al. Sparfloxacin in the field of dermatology. Chemotherapy (Tokyo) 39 (Suppl. 4): 145–148, 1991

    CAS  Google Scholar 

  • Aoki N, Usuda Y, Koda Y, Wakabayashi N, Hayashi S, et al. Clinical pharmacology and efficacy of sparfloxacin. Chemotherapy (Tokyo) 39 (Suppl. 4): 261–271, 1991

    Google Scholar 

  • Chang T, Black A, Dunky A, Wolf R, Sedman A, et al. Pharmacokinetics of intravenous and oral enoxacin in healthy volunteers. Journal of Antimicrobial Chemotherapy 21 (Suppl. B): 49–56, 1988

    PubMed  CAS  Google Scholar 

  • Cohen MA, Huband MD, Mailloux GB, Yoder SL, Roland GE, et al. In vitro activity of sparfloxacin (CI-978, AT-4140, and PD-131501): a quinolone with high activity against gram-positive bacteria. Diagnostic Microbiology and Infectious Diseases 14: 403–415, 1991

    Article  CAS  Google Scholar 

  • Cooper MA, Andrews JM, Ashby JP, Mattews RS, Wise R. In-vitro activity of sparfloxacin, a new quinolone antimicrobial agent. Journal of Antimicrobial Chemotherapy 26: 667–676, 1990

    Article  PubMed  CAS  Google Scholar 

  • Doebbeling BN, Pfaller MA, Bale MJ, Wenzel RP. Comparative in vitro activity of the new quinolone sparfloxacin (CI-978, AT-4140) against nosocomial gram-negative bloodstream isolates. European Journal of Clinical Microbiology and Infectious Diseases 9: 298–301, 1990

    Article  CAS  Google Scholar 

  • Drusano GL, Plaisance KI, Forrest A, Standiford HC. Dose ranging study and constant infusion evaluation of ciprofloxacin. Antimicrobial Agents and Chemotherapy 30: 440–443, 1986

    Article  PubMed  CAS  Google Scholar 

  • Giamarellou H, Voutsinas D, Xirouchaki E. Comparative in vitro activity of sparfloxacin (AT4140, RP-64206, SPFX) against 275 multiresistant clinical isolates. Journal of Chemotherapy 4: 12–15, 1992

    PubMed  CAS  Google Scholar 

  • Goto H, Goto M, Oka S, Urayama K, Kimura S, et al. Evaluation of antibacterial activity of sparfloxacin using in vitro pharmacokinetic system. Chemotherapy (Tokyo) 39 (Suppl. 4): 54–58, 1991a

    CAS  Google Scholar 

  • Goto S, Miyazaki S, Tsuji A, Kaneko Y. In vitro and in vivo antibacterial activities of a new quinolone, sparfloxacin. Chemotherapy (Tokyo) 39 (Suppl. 4): 13–29, 1991b

    CAS  Google Scholar 

  • Gouhara Y, Oowaki T, Shimizu Y. Fundamental and clinical studies on sparfloxacin (SPFX). Chemotherapy (Tokyo) 39 (Suppl. 4): 497–503, 1991

    Google Scholar 

  • Hara J, Ozawa T, Araki K, Mitsuda H. Sparfloxacin in anterior eye infections. Chemotherapy (Tokyo) 39 (Suppl. 4): 697–700, 1991

    Google Scholar 

  • Harada Y, Hirakawa K, Tagashira N, Suzuki M, Kawamura S, et al. Clinical studies of sparfloxacin against suppurative otitis media. Chemotherapy (Tokyo) 39 (Suppl. 4): 670–680, 1991

    Google Scholar 

  • Imagawa Y, Saito M, Matsubara Y, Tomizawa I, Takizawa Y, et al. Clinical study of sparfloxacin on infectious enteritis. Chemotherapy (Tokyo) 39 (Suppl. 4): 454–465, 1991

    Google Scholar 

  • Ito K, Mikamo H, Tamaya T, Yamada Y, Hayashi M, et al. Sparfloxacin in the obstetrical and gynecological field. Chemotherapy (Tokyo) 39 (Suppl. 4): 719–725, 1991

    Google Scholar 

  • Kaji M, Saito A, Shimada J, Ohmori M, Shiba K, et al. Clinical studies on NY-198. Chemotherapy (Tokyo) 36 (Suppl. 2): 513–526, 1988

    Google Scholar 

  • Kato M, Kuze F. In vitro activities of a new quinolone derivative, sparfloxacin, against Mycobacterium tuberculosis, Mycobacterium avium complex, Mycobacterium kansasii, and Mycobacterium fortuitum. Chemotherapy (Tokyo) 39 (Suppl. 4): 101–106, 1991

    CAS  Google Scholar 

  • Kawada Y, Kumamoto Y, Aso Y, Oshi M, Machida T, et al. Comparative study of sparfloxacin and enoxacin in complicated urinary tract infections. Chemotherapy (Tokyo) 39 (Suppl. 4): 571–588, 1991

    Google Scholar 

  • Kawahara K, Kawahara M, Goto T, Ohi Y. Penetration of sparfloxacin into the human spinal fluid: a comparative study with 5 other fluoroquinolones. Chemotherapy (Tokyo) 39 (Suppl. 4): 149–157, 1991

    Google Scholar 

  • Kawai S, Yada K, Hida T, Fujiwara T. Basic and clinical studies of sparfloxacin in the field of ophthalmology. Rinsho Ganka 45: 1891–1894, 1991

    Google Scholar 

  • Kojima T, Inoue M, Mitsuhashi S. In vitro activity of AT-4140 against clinical bacterial isolates. Antimicrobial Agents and Chemotherapy 33: 1980–1988, 1989

    Article  PubMed  CAS  Google Scholar 

  • Kurobe N, Ohue T, Yamaguchi T, Nakamura S. Bioassay method for sparfloxacin in body fluids. Chemotherapy (Tokyo) 39 (Suppl. 4): 116–122, 1991

    CAS  Google Scholar 

  • Lode H, Hoeffken G, Olschewski P, Sievers B, Kirch A, et al. Pharmacokinetics of ofloxacin after parenteral and oral administration. Antimicrobial Agents and Chemotherapy 31: 1338–1342, 1987

    Article  PubMed  CAS  Google Scholar 

  • Mahr G, Seelmann R, Gottschalk B, Stephan U, Sorgel F. No effect of sparfloxacin on the metabolism of theophylline in man. Proceedings of the 30th Interscience Conference on Antimicrobial Agents and Chemotherapy, p. 296, Atlanta, October 21–24, 1990

  • Matsunaga Y, Miyazaki H, Oh-e Y, Nambu K, Furukawa H, et al. Disposition and metabolism of [14C]sparfloxacin in the rat. Arzneimittel-Forschung 41 (2): 747–759, 1991

    PubMed  CAS  Google Scholar 

  • Matsushima T, Kawanishi M, Kimura M, Tomizawa S, Kobashi Y, et al. Clinical study of sparfloxacin in respiratory infections and its concentration in pleural fluid. Chemotherapy (Tokyo) 39 (Suppl. 4): 798–803, 1991

    Google Scholar 

  • Matsuura T, Adachi S, Suzuki K, Yamamoto T. Basic and clinical studies on sparfloxacin in elderly subjects. Chemotherapy (Tokyo) 39 (Suppl. 4): 286–291, 1991

    Google Scholar 

  • Mignot A, Douin MJ, Millerioux L, Chassard D, Thebault JJ, et al. Effect of aluminum hydroxide antacid on the pharmacokinetics of the new quinolone sparfloxacin. Proceedings of the 30th Interscience Conference on Antimicrobial Agents and Chemotherapy, Atlanta, October 21–24, Abstract no. 1250, p. 294, 1990

  • Miki F, Ikuno Y, Murata A, Tanizawa S, Sakamoto K, et al. Basic and clinical studies of sparfloxacin. Chemotherapy (Tokyo) 39 (Suppl. 4): 292–305, 1991

    Google Scholar 

  • Miyamoto T, Matsumoto J, Chiba K, Egawa H, Shibamori K, et al. Synthesis and structure-activity relationships of 5-substituted 6,8-difluoroquinolones, including sparfloxacin, a new quinolone antibacterial agent with improved potency. Journal of Medicinal Chemistry 33: 1645–1656, 1990

    Article  PubMed  CAS  Google Scholar 

  • Mizuki Y, Kamaura M, Yamaguchi Y, Sekine Y, Hashimoto M. Interaction of enoxacin with theophylline in rats. Arzneimittel-Forschung 39: 593–597, 1989

    PubMed  CAS  Google Scholar 

  • Mizuki Y, Yamaguchi T, Sekine Y, Hashimoto M. Effect of sparfloxacin on theophylline pharmacokinetics in rats. Proceedings of the 30th Interscience Conference on Antimicrobial Agents and Chemotherapy, Atlanta, October 21–24, Abstract no. 1252, p. 295, 1990

  • Montay G, Bruno R, Thebault JJ, Vergniol JC, Chassard D, et al. Dose-dependent pharmacokinetic study of sparfloxacin (SPFX) in healthy young volunteers. Proceedings of the 30th Interscience Conference on Antimicrobial Agents and Chemotherapy, Atlanta, October 21–24, Abstract no. 1248, p. 294, 1990

  • Morimoto K, Kinoshita H, Nakatani S, Lee K, Sakai K, et al. Sparfloxacin in the treatment of patients with surgical infections. Chemotherapy (Tokyo) 39 (Suppl. 4): 601–619, 1991

    Google Scholar 

  • Murakami T, Nakahara K, Matsuo M, Masaoka T, Fujiwara A. Sparfloxacin in obstetrics and gynecology. Chemotherapy (Tokyo) 39 (Suppl. 4): 734–740, 1991

    Google Scholar 

  • Naitoh H, Tomita F. Serum levels and saliva concentration of sparfloxacin (SPFX). Shiyaku Ryouhou 10: 85–90, 1991

    CAS  Google Scholar 

  • Nakamura S, Kurobe N, Ohue T, Hashimoto M, Shimizu M. Pharmacokinetics of a novel quinolone, AT-4140, in animals. Antimicrobial Agents and Chemotherapy 34: 89–93, 1990

    Article  PubMed  CAS  Google Scholar 

  • Nakamura S, Minami A, Nakata K, Kurobe N, Kouno K, at al. In vitro and in vivo antibacterial activities of AT-4140, a new broad-spectrum quinolone. Antimicrobial Agents and Chemotherapy 33: 1167–1173, 1989

    Article  PubMed  CAS  Google Scholar 

  • Nakamura S, Nakata K, Kashimoto S, Kajikawa F, Okazaki Y, et al. Antichlamydial activity of sparfloxacin. Chemotherapy (Tokyo) 39 (Suppl. 4): 93–100, 1991

    CAS  Google Scholar 

  • Nakashima M, Kanamaru M, Uematsu T, Takiguchi Y. Phase I study of pyridone carboxylic acid antibacterial agent, sparfloxacin. Rinshou Iyaku 7: 1639–1684, 1991

    Google Scholar 

  • Nakashima M, Uematsu T, Kanamaru M, Naganuma H. Clinical pharmacology of antimicrobial pyridonecarboxylic acids (I): comparative study on pharmacokinetics in healthy humans and antimicrobial activity. Chemotherapy (Tokyo) 38: 533–539, 1990

    CAS  Google Scholar 

  • Nakatani T, Tsuboi E, Narui K, Chonabayashi N, Nakamori Y, et al. Clinical efficacy of sparfloxacin in the respiratory tract infections and its pharmacokinetics in sputum. Chemotherapy (Tokyo) 39 (Suppl. 4): 245–249, 1991

    Google Scholar 

  • Niki T, Soejima R, Kawane H, Sumi M, Umeki S. New synthetic quinolone anti-bacterial agents and serum concentration of theophylline. Chest 92: 663–669, 1987

    Article  PubMed  CAS  Google Scholar 

  • Nishino T, Nakamura M, Wano T, Otsuki M. In vitro and in vivo antibacterial activities of sparfloxacin, a new quinolone. Chemotherapy (Tokyo) 39 (Suppl. 4): 59–77, 1991

    Google Scholar 

  • Nogita T, Ishibashi Y. The penetration of sparfloxacin into human plasma and skin tissue. Journal of Antimicrobial Chemotherapy 28: 313–314, 1991

    Article  PubMed  CAS  Google Scholar 

  • Oguri T, Hayashi Y. In vitro activity of sparfloxacin against clinical isolates. Chemotherapy (Tokyo) 39 (Suppl. 4): 37–46, 1991

    CAS  Google Scholar 

  • Oishi K, Matsumoto K, Watanabe K, Takasugi M, Utsunomiya Y, et al. In vitro activity, pharmacokinetics and therapeutic efficacy of sparfloxacin, a new quinolone: usefulness in lower respiratory infections. Chemotherapy (Tokyo) 39 (Suppl. 4): 366–377, 1991

    Google Scholar 

  • Okimoto N, Niki Y, Sumi M, Nakagawa Y, Soejima R. Effect of sparfloxacin on plasma concentration of theophylline. Chemotherapy (Tokyo) 39 (Suppl. 4): 158–160, 1991

    CAS  Google Scholar 

  • Onodera S, Kiyota H, Goto H, Kawahara M, Igarashi H, et al. Clinical efficacy of sparfloxacin in genitourinary tract infections. Chemotherapy (Tokyo) 39 (Suppl. 4): 481–488, 1991

    Google Scholar 

  • Qadri SM, Ueno Y, Burns JJ, Alomodovar E, Rabea N. In vitro activity of sparfloxacin (CI978), a new broad-spectrum fluoroquinolone. Chemotherapy (Switzerland) 38: 99–106, 1992

    CAS  Google Scholar 

  • Raoof S, Wollschlager C, Khan FA. Ciprofloxacin increases serum levels of theophylline. American Journal of Medicine 82 (Suppl. 4A): 115–118, 1987

    PubMed  CAS  Google Scholar 

  • Saito A, Tomizawa M, Nakayama I, Sato K. Basic and clinical studies on sparfloxacin. Chemotherapy (Tokyo) 39 (Suppl. 4): 203–212, 1991

    Google Scholar 

  • Sakashita S, Yokogawa M, Yamaguchi T, Sekine Y. Pharmacokinetics of sparfloxacin in man. Xenobiotic Metabolism and Disposition 6: 43–51, 1991

    CAS  Google Scholar 

  • Sato A, Okano A, Chida K, Iwata M, Okano H, et al. Basic and clinical studies on sparfloxacin in respiratory tract infection. Chemotherapy (Tokyo) 39 (Suppl. 4): 272–279, 1991

    Google Scholar 

  • Shimada J, Saito A, Shiba K, Hojo T, Kaji M, et al. Pharmacokinetics and clinical studies of sparfloxacin. Chemotherapy (Tokyo) 39 (Suppl. 4): 234–244, 1991

    Google Scholar 

  • Shimada J, Yamaji T, Ueda Y, Uchida H, Kasajima H, et al. Mechanism of renal excretion of AM-715, a new quinolonecarboxylic acid derivative, in rabbits, dogs, and humans. Antimicrobial Agents and Chemotherapy 23: 1–7, 1983

    Article  PubMed  CAS  Google Scholar 

  • Soejima R, Kawame H, Okimoto N, Sumi M, Saito A, et al. Comparative study of sparfloxacin and ofloxacin in bacterial pneumonia by the double blind method. Chemotherapy (Tokyo) 39 (Suppl. 4): 428–453, 1991b

    Google Scholar 

  • Soejima R, Kawane H, Okimoto N, Tatara O, Takebe K, et al. Comparative study of sparfloxacin and ofloxacin in chronic respiratory tract infections by the double blind method. Chemotherapy (Tokyo) 39 (Suppl. 4): 405–428, 1991a

    Google Scholar 

  • Stuck AE, Frey FJ, Heizmann P, Brandt R, Weidekmann E. Pharmacokinetics and metabolism of intravenous and oral fleroxacin in subjects with normal and impaired renal function and in patients on continuous ambulatory peritoneal dialysis. Antimicrobial Agents and Chemotherapy 33: 373–381, 1989

    Article  PubMed  CAS  Google Scholar 

  • Suzuki K, Horiba M, Naide Y, Shinoda M, Hibi H. Clinical and bacteriological study of sparfloxacin on bacterial prostatitis. Hinyokika Kiyou 38: 121–128, 1992

    CAS  Google Scholar 

  • Takagi K, Yamaki K, Nadai M, Kuzuya T, Hasegawa T. Effect of a new quinolone, sparfloxacin, on the pharmacokinetics of theophylline in asthmatic patients. Antimicrobial Agents and Chemotherapy 35: 1137–1141, 1991

    Article  PubMed  CAS  Google Scholar 

  • Takahashi H, Mochizuki A, Takahashi N, Nishikawa T, Amano Y, et al. A multicenter double blind comparative study of sparfloxacin and enoxacin in the treatment of skin and soft tissue infections. Chemotherapy (Tokyo) 39 (Suppl. 4): 648–669, 1991

    Google Scholar 

  • Takamoto M, Kitahara Y, Ishibashi T, Shinoda A. Clinical trial experience with sparfloxacin against respiratory infections and pharmacokinetic analysis. Chemotherapy (Tokyo) 39 (Suppl. 4): 337–341, 1991

    Google Scholar 

  • Takeuchi T, Yamamoto N, Takahashi Y, Shinoda I, Ito Y, et al. Pharmacokinetic analysis on penetration of sparfloxacin into prostatic tissue. Chemotherapy (Tokyo) 39 (Suppl. 4): 138–144, 1991

    Google Scholar 

  • Tanimura H, Ishimoto K, Yukawa H, Sakamoto Y, Ohnishi H, et al. Excretion into bile and gallbladder tissue level of a new quinolone, sparfloxacin, and its clinical efficacy on surgical infections. Chemotherapy (Tokyo) 39 (Suppl. 4): 620–632, 1991a

    Google Scholar 

  • Tanimura M, Kataoka S, Fujita Y. Basic and clinical studies of sparfloxacin in urinary tract infections. Chemotherapy (Tokyo) 39 (Suppl. 4): 523–530, 1991b

    Google Scholar 

  • Thebault JJ, Montay G, Ebmeier M, Douin MJ, Millerioux L, et al. Effect of food on the bioavailability of the new quinolone sparfloxacin. Proceedings of the 30th Interscience Conference on Antimicrobial Agents and Chemotherapy, Atlanta, October 21–24, Abstract no. 1249, p. 294, 1990

  • Toyoura T, Morishima T. Blood levels of exodontia wound after oral administration of sparfloxacin (AT-4140). Shiyaku Ryouhou 10: 91–96, 1991

    Google Scholar 

  • Uchizono A, Shima T, Ohyama M, Fukami K, Miyazaki Y, et al. Penetration of sparfloxacin into tissues and secretions in bacterial infections in otolaryngological field. Jibi to Rinsho 37: 941–948, 1991

    Google Scholar 

  • Ueda S, Eto K. Fundamental and clinical studies on sparfloxacin. Chemotherapy (Tokyo) 39 (Suppl. 4): 538–544, 1991

    Google Scholar 

  • Watanabe K, Kato N, Muto Y, Bando K, Tanaka Y, et al. In vitro activities of a new quinolone, sparfloxacin, against anaerobic bacteria. Chemotherapy (Tokyo) 39 (Suppl. 4): 107–115, 1991

    CAS  Google Scholar 

  • Weidekamm E, Portmann R, Partos C, Dell D, Lucker PW. Single and multiple-dose pharmacokinetics of fleroxacin, a trifluorinated quinolone, in humans. Antimicrobial Agents and Chemotherapy 31: 1909–1914, 1987

    Article  PubMed  CAS  Google Scholar 

  • Wijnands WJA, Vree TB, Baars AM, van Herwaarden CLA. Pharmacokinetics of enoxacin and its penetration into bronchial secretions and lung tissue. Journal of Antimicrobial Chemotherapy 21 (Suppl. B): 67–77, 1988

    PubMed  CAS  Google Scholar 

  • Wijnands WJA, Vree TB, van Herwaarden CLA. The influence of quinolone derivatives on theophylline clearance. British Journal of Clinical Pharmacology 22: 677–683, 1986

    Article  PubMed  CAS  Google Scholar 

  • Wingender W, Beermann D, Foster D. Mechanism of renal excretion of ciprofloxacin (Bay 9867), a new quinolone carboxylic derivative, in humans. Chemotherapy 4 (Suppl. 2): 403–404, 1985

    Google Scholar 

  • Yamada H, Katoh O, Hiura K, Aoki Y, Kuroki S, et al. Clinical effects of sparfloxacin on respiratory tract infections and penetration of this agent into sputum. Chemotherapy (Tokyo) 39 (Suppl. 4): 350–356, 1991

    Google Scholar 

  • Yamaguchi T, Yokogawa M, Hashizume T, Baba M, Higuchi Y, et al. Pharmacokinetics of sparfloxacin in rats, dogs and monkeys. Xenobiotic Metabolism and Disposition 6: 33–41, 1991a

    CAS  Google Scholar 

  • Yamaguchi T, Yokogawa M, Sakashita M, Itokawa A, Kurono M, et al. Metabolism of sparfloxacin in rats, dogs, monkeys and man. Xenobiotic Metabolism and Disposition 6: 2132, 1991c

    Google Scholar 

  • Yamaguchi T, Yokogawa M, Sekine Y. Renal excretion mechanism of sparfloxacin. Xenobiotic Metabolism and Disposition 6: 61–65, 1991d

    CAS  Google Scholar 

  • Yamaguchi T, Yokogawa M, Sekine Y, Hashimoto M. Intestinal absorption characteristics of sparfloxacin. Xenobiotic Metabolism and Disposition 6: 53–59, 1991b

    CAS  Google Scholar 

  • Yamamoto Y, Matsumoto S, Ikeda M, Kodama H. Penetration of sparfloxacin into the skin. Chemotherapy (Tokyo) 39 (Suppl. 4): 741–742, 1991

    CAS  Google Scholar 

  • Yokota T, Kanda K, Arai K. In vitro antibacterial activity of sparfloxacin, its synergy with the complement of mouse cultured macrophages in the bactericidal effect, and cytotoxicity to mammalian cells. Chemotherapy (Tokyo) 39 (Suppl. 4): 30–36, 1991

    CAS  Google Scholar 

  • Yoshitomi Y, Mitsutake K, Higashiyama Y, Matsuda H, Miyazaki Y, et al. Laboratory and clinical studies on sparfloxacin. Chemotherapy (Tokyo) 39 (Suppl. 4): 357–365, 1991

    Google Scholar 

  • Yura J, Shinagawa N, Ishikawa S, Mashita K, Suzui K, et al. Basic and clinical studies on sparfloxacin in the field of surgery. Chemotherapy (Tokyo) 39 (Suppl. 4): 594–600, 1991

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Medical Science, St Marianna University School of Medicine, Sugao 2-16-1, Miyamae-ku, Kawasaki, Kanagawa, 216, Japan

    Jingoro Shimada

  2. Department of Dermatology, Faculty of Medicine, University of Tokyo, Tokyo, Japan

    Toshitatsu Nogita & Yasumasa Ishibashi

  3. Department of Dermatology, Tokyo Women’s Medical College, Tokyo, Japan

    Toshitatsu Nogita

Authors
  1. Jingoro Shimada
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Toshitatsu Nogita
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yasumasa Ishibashi
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Shimada, J., Nogita, T. & Ishibashi, Y. Clinical Pharmacokinetics of Sparfloxacin. Clin. Pharmacokinet. 25, 358–369 (1993). https://doi.org/10.2165/00003088-199325050-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003088-199325050-00002

Search

Navigation